Cargando…

New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma

Mesothelin is an emerging cell surface target in mesothelioma and other solid tumors. Most antibody drug candidates recognize highly immunogenic Region I (296–390) on mesothelin. Here, we report a group of high-affinity non-Region I rabbit monoclonal antibodies. These antibodies do not compete for m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yi-Fan, Phung, Yen, Gao, Wei, Kawa, Seiji, Hassan, Raffit, Pastan, Ira, Ho, Mitchell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440525/ https://www.ncbi.nlm.nih.gov/pubmed/25996440 http://dx.doi.org/10.1038/srep09928

Ejemplares similares

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma
por: Inaguma, Shingo, et al.
Publicado: (2017)

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
por: Mazor, Ronit, et al.
Publicado: (2016)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
por: Liu, Wenlong, et al.
Publicado: (2022)

Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
por: Zhang, Jingli, et al.
Publicado: (2014)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies
por: Zhan, Jingyu, et al.
Publicado: (2023)

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
por: Tomar, Sakshi, et al.
Publicado: (2022)

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
por: Thomas, Anish, et al.
Publicado: (2015)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Multiple proteases are involved in mesothelin shedding by cancer cells
por: Liu, Xiufen, et al.
Publicado: (2020)

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
por: Gubbels, Jennifer AA, et al.
Publicado: (2006)

Safety and biodistribution of (111)In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging
por: Lindenberg, Liza, et al.
Publicado: (2015)

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma
por: de Fonseka, Duneesha, et al.
Publicado: (2018)

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma
por: Kalra, Neetu, et al.
Publicado: (2015)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015)

Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats
por: Sathyanarayana, Bangalore K, et al.
Publicado: (2009)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
por: Mattoo, Abid R., et al.
Publicado: (2013)

The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy
por: Xiang, Xinran, et al.
Publicado: (2011)

Monoclonal Antibody Recognizing a Core Epitope on Mucin
por: Devine, Peter L., et al.
Publicado: (1998)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway
por: Liu, Xiu-Fen, et al.
Publicado: (2017)

Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma
por: Yu, Liping, et al.
Publicado: (2010)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5
por: Xia, Lin, et al.
Publicado: (2016)

Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B
por: Liu, Jinyu, et al.
Publicado: (2022)

Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1
por: Matsuura, Rieko, et al.
Publicado: (2018)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015)

Characterization of a panel of monoclonal antibodies recognizing specific epitopes on GFAP
por: Lin, Ni-Hsuan, et al.
Publicado: (2017)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors
por: Brockstedt, Dirk G, et al.
Publicado: (2013)

G196 epitope tag system: a novel monoclonal antibody, G196, recognizes the small, soluble peptide DLVPR with high affinity
por: Tatsumi, Kasumi, et al.
Publicado: (2017)

In Vivo Imaging of Human Malignant Mesothelioma Grown Orthotopically in the Peritoneal Cavity of Nude Mice
por: Feng, Mingqian, et al.
Publicado: (2011)

Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells
por: He, Xiaoqing, et al.
Publicado: (2017)

Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression
por: Kojima, Masataka, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r1e96hjsp2a024n8chgsie50bk